Diabetes Drug Might Be Tied to Increased Amputation Risk, FDA Cautions (FREE)

By Amy Orciari Herman Edited by Susan Sadoughi, MD The FDA is investigating a potentially increased risk for leg and foot amputations among patients taking the diabetes drug canagliflozin. The sodium-glucose cotransporter-2 inhibitor is sold under the …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news